Neurogenic dysphagia: current pharmacogenomic perspectives

Abstract

Neurogenic dysphagia (ND) is characterized by a swallowing disorder where nervous system, muscle, and neuromuscular diseases are involved. DRD1, COMT, BDNF, and APOE are genes that may have a predictive role in the occurrence and evolution of ND. Many drugs that improve swallowing or can induce or exacerbate swallowing difficulties are related to dopamine metabolism and substance P. These pharmacological treatments for ND include dopamine precursors (levodopa), dopamine agonists (amantadine, apomorphine, cabergoline, and rotigotine), and TRP channel activators (capsaicin, piperine, and menthol). Since treatment outcomes are highly dependent on the genomic profiles of ND patients, personalized treatments should rely on pharmacogenetic procedures to optimize therapeutic interventions. Knowledge of the pharmacogenetic profiles of these drugs would minimize the occurrence of adverse drug reactions (especially to antidopaminergic medications) that may induce dysphagia and optimize pharmacological treatment that can ameliorate it. This knowledge should also be applied to the use of medications that control symptoms associated with dysphagia, such as sialorrhea, xerostomia, reflux, or hiccups.

Keywords

Oropharyngeal dysphagia / neurogenic dysphagia / pharmacogenomics / dopamine / dopaminergics / antidopaminergics / TRP genes

References

[1] PanebiancoM,MasieroS.Dysphagia in neurological diseases: a literature review.Neurol Sci2020;41:3067-73 PMCID:PMC7567719

[2] WarneckeT,SchroederJ.Neurogenic dysphagia: systematic review and proposal of a classification system.Neurology2021;96:e876-89

[3] SuraL,CarnabyG.Dysphagia in the elderly: management and nutritional considerations.Clin Interv Aging2012;7:287-98 PMCID:PMC3426263

[4] WirthR,BeckAM.Oropharyngeal dysphagia in older persons - from pathophysiology to adequate intervention: a review and summary of an international expert meeting.Clin Interv Aging2016;11:189-208 PMCID:PMC4770066

[5] NascimentoW,AcedoS.Effect of aging, gender and sensory stimulation of TRPV1 Receptors with capsaicin on spontaneous swallowing frequency in patients with oropharyngeal dysphagia: a proof-of-concept study.Diagnostics (Basel)2021;11:461 PMCID:PMC7999082

[6] DziewasR,AroyoI.Diagnosis and treatment of neurogenic dysphagia - S1 guideline of the German society of neurology.Neurol Res Pract2021;3:23 PMCID:PMC8094546

[7] SpeyerR,HeijnenM.Effects of therapy in oropharyngeal dysphagia by speech and language therapists: a systematic review.Dysphagia2010;25:40-65 PMCID:PMC2846331

[8] WarneckeT,LangmoreS. Neurogenic dysphagia. 1st ed. Cham: Springer, 2021.

[9] StoschusB.Drug-induced dysphagia.Dysphagia1993;8:154-9

[10] SokoloffLG.Neuroleptic-induced dysphagia.Dysphagia1997;12:177-9

[11] CrouseEL,BozymskiKM.Dysphagia with second-generation antipsychotics: A case report and review of the literature.Ment Health Clin2017;7:56-64 PMCID:PMC6007670

[12] WolfU,WalterG.Prevalence of oropharyngeal dysphagia in geriatric patients and real-life associations with diseases and drugs.Sci Rep2021;11:21955 PMCID:PMC8578645

[13] EisenhoferG,GoldsteinDS.Catecholamine metabolism: a contemporary view with implications for physiology and medicine.Pharmacol Rev2004;56:331-49

[14] VidalP-P. Chapter 30: Vestibular system. In: Paxinos G, editor. The rat nervous system, 3dr ed. London: Academic Press, 2004; pp. 965-96.

[15] TritschNX.Dopaminergic modulation of synaptic transmission in cortex and striatum.Neuron2012;76:33-50 PMCID:PMC4386589

[16] BiegerD,HockmanC.Dopaminergic influences on swallowing.Neuropharmacology1977;16:245-52

[17] JiaYX,OhruiT,SasakiH.Dopamine D1 receptor antagonist inhibits swallowing reflex in guinea pigs.Am J Physiol1998;274:R76-80

[18] GantoisI,JiangL.Ablation of D1 dopamine receptor-expressing cells generates mice with seizures, dystonia, hyperactivity, and impaired oral behavior.Proc Natl Acad Sci USA2007;104:4182-7 PMCID:PMC1820729

[19] ParkHY,OhHM,ParkGY.Potential prognostic impact of dopamine receptor d1 (.rs453212:675060 PMCID:PMC8277925

[20] NimmonsD,PaytonA.A novel association between COMT and BDNF gene polymorphisms and likelihood of symptomatic dysphagia in older people.Neurogastroenterol Motil2015;27:1223-31

[21] WarneckeT,TeismannI.Endoscopic characteristics and levodopa responsiveness of swallowing function in progressive supranuclear palsy.Mov Disord2010;25:1239-45

[22] WarneckeT,SchröderJB.Levodopa responsiveness of dysphagia in advanced Parkinson’s disease and reliability testing of the FEES-Levodopa-test.Parkinsonism Relat Disord2016;28:100-6

[23] HunterPC,AustinS,HughesAJ.Response of parkinsonian swallowing dysfunction to dopaminergic stimulation.J Neurol Neurosurg Psychiatry1997;63:579-83 PMCID:PMC2169826

[24] HiranoM,SakamotoH,KusunokiS.Rotigotine transdermal patch improves swallowing in dysphagic patients with parkinson’s disease.Dysphagia2015;30:452-6

[25] HiranoM,FukudaK,NakamuraY.Effects of the rotigotine transdermal patch versus oral levodopa on swallowing in patients with Parkinson’s disease.J Neurol Sci2019;404:5-10

[26] TisonF,GuatterieM.Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson’s disease.Mov Disord1996;11:729-32

[27] MichouE,HarrisM.Characterization of corticobulbar pharyngeal neurophysiology in dysphagic patients with Parkinson’s disease.Clin Gastroenterol Hepatol2014;12:2037-45.e1

[28] ChangMC,LeeBJ.Effectiveness of pharmacologic treatment for dysphagia in Parkinson’s disease: a narrative review.Neurol Sci2021;42:513-9

[29] KobayashiH,SekizawaK,SasakiH.Levodopa and swallowing reflex.Lancet1996;348:1320-1

[30] AraiT,YoshimiN,FujiwaraH.Cabergoline and silent aspiration in elderly patients with stroke.J Am Geriatr Soc2003;51:1815-6

[31] NakagawaT,SekizawaK,SasakiH.Amantadine and pneumonia.Lancet1999;353:1157

[32] ApaydinH,OzekmekçiS.Broad bean (Vicia faba) - A natural source ofL-dopa-Prolongs “on” periods in patients with Parkinson’s disease who have “on-off” fluctuations.Mov Disord2000;15:164-6

[33] KanazawaK.High content of dopamine, a strong antioxidant, in Cavendish banana.J Agric Food Chem2000;48:844-8

[34] PulikkalpuraH,MathewPJ.Levodopa in Mucuna pruriens and its degradation.Sci Rep2015;5:11078 PMCID:PMC4460905

[35] KatzenschlagerR,MansonA.Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study.J Neurol Neurosurg Psychiatry2004;75:1672-7 PMCID:PMC1738871

[36] CacabelosR,MartínezO.Atremorine in parkinson’s disease: from dopaminergic neuroprotection to pharmacogenomics.Med Res Rev2021;41:2841-86

[37] CacabelosR. World guide for drug use and pharmacogenomics. Corunna, Spain: EuroEspes Publishing Co., 2012.

[38] Soler-AlfonsoC,TurkCL.Potocki-Lupski syndrome: a microduplication syndrome associated with oropharyngeal dysphagia and failure to thrive.J Pediatr2011;158:655-659.e2 PMCID:PMC3059370

[39] MichałowskaM,JówkoE.Gene polymorphisms and motor levodopa-induced complications in Parkinson’s disease.Brain Behav2020;10:e01537 PMCID:PMC7066344

[40] ZhaoC,ZhangB,ZhangJ.Genetic variations in catechol-O-methyltransferase gene are associated with levodopa response variability in Chinese patients with Parkinson’s disease.Sci Rep2020;10:9521 PMCID:PMC7293305

[41] RieckM,Callegari-JacquesSM.Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson’s disease patients?.Pharmacogenomics2015;16:573-82

[42] Schumacher-SchuhAF,RieckM.Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson’s disease patients.Pharmacogenomics J2014;14:289-94

[43] RieckM,AltmannV.DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson’s disease patients.Pharmacogenomics2012;13:1701-10

[44] MoreauC,CorvolJC.Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson’s disease.Brain2015;138:1271-83 PMCID:PMC5963414

[45] AhmedSS,KumarS.Association between MDR1 gene polymorphisms and Parkinson’s disease in Asian and Caucasian populations: a meta-analysis.J Neurol Sci2016;368:255-62

[46] LohrKM,SalahpourA.Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.Eur J Neurosci2017;45:20-33 PMCID:PMC5209277

[47] PougetJG,TiwariAK.Pharmacogenetics and outcome with antipsychotic drugs.Dialogues Clin Neurosci2014;16:555-66 PMCID:PMC4336924

[48] YoshidaK.Pharmacogenetics of antipsychotic drug treatment: update and clinical implications.Mol Neuropsychiatry2020;5:1-26 PMCID:PMC7206586

[49] VenkatachalamK.TRP channels.Annu Rev Biochem2007;76:387-417 PMCID:PMC4196875

[50] KichkoTI,KobalG.The roles of TRPV1, TRPA1 and TRPM8 channels in chemical and thermal sensitivity of the mouse oral mucosa.Eur J Neurosci2018;47:201-10

[51] Alvarez-BerdugoD,FarréR.Localization and expression of TRPV1 and TRPA1 in the human oropharynx and larynx.Neurogastroenterol Motil2016;28:91-100

[52] HossainMZ,UnnoS,KitagawaJ.Activation of TRPV1 and TRPM8 channels in the larynx and associated laryngopharyngeal regions facilitates the swallowing reflex.Int J Mol Sci2018;19:4113 PMCID:PMC6321618

[53] PeierAM,HergardenAC.A TRP channel that senses cold stimuli and menthol.Cell2002;108:705-15

[54] Alvarez-BerdugoD,ArreolaV,MolinaL.A comparative study on the therapeutic effect of TRPV1, TRPA1, and TRPM8 agonists on swallowing dysfunction associated with aging and neurological diseases.Neurogastroenterol Motil2018;30:e13185

[55] ChengI,HamdyS.Effects of pharmacological agents for neurogenic oropharyngeal dysphagia: A systematic review and meta-analysis.Neurogastroenterol Motil2022;34:e14220

[56] SnitkerS,ShenH.Effects of novel capsinoid treatment on fatness and energy metabolism in humans: possible pharmacogenetic implications.Am J Clin Nutr2009;89:45-50 PMCID:PMC3151435

[57] ShamsiS,TanRS,LimLY.Curcumin, piperine, and capsaicin: a comparative study of spice-mediated inhibition of human cytochrome P450 isozyme activities.Drug Metab Dispos2017;45:49-55

[58] DonCG.In Silico Pharmacogenetics CYP2D6 Study Focused on the Pharmacovigilance of Herbal Antidepressants.Front. Pharmacol2020;11:683 PMCID:PMC7237870

[59] IkedaJ,SaekiK,TakayamaM.Perindopril increases the swallowing reflex by inhibiting substance P degradation and tyrosine hydroxylase activation in a rat model of dysphagia.Eur J Pharmacol2015;746:126-31

[60] ShinoharaY.Post-stroke pneumonia prevention by angiotensin-converting enzyme inhibitors: results of a meta-analysis of five studies in Asians.Adv Ther2012;29:900-12

[61] LeeJS,MaHM.Does low dose angiotensin converting enzyme inhibitor prevent pneumonia in older people with neurologic dysphagia - a randomized placebo-controlled trial.J Am Med Dir Assoc2015;16:702-7

[62] ChenD,JiangQ,HuW.Role of levetiracetam in the rehabilitation of dysphagia due to stroke.Int J of Pharmacol2017;13:603-11

[63] MonroeMD,BennettR.Citric acid cough reflex test: Establishing normative data.J Speech Lang Hear2014;17:216-24

[64] FujiwaraK,ShimizuY.A novel reflex cough testing device.BMC Pulm Med2017;17:19 PMCID:PMC5242037

[65] NurmiHM,BrannanJD.Comparison of mannitol and citric acid cough provocation tests.Respir Med2019;158:14-20

[66] KriegerDW.Therapeutic drug approach to stimulate clinical recovery after Brain injury.Front Neurol Neurosci2013;76-87

[67] JayasekeranV,HollandG.Val66Met in brain-derived neurotrophic factor affects stimulus-induced plasticity in the human pharyngeal motor cortex.Gastroenterology2011;141:827-836.e1

[68] OhHM,ParkHY,ParkGY.Role of rs6265 BDNF polymorphisms and post-stroke dysphagia recovery-A prospective cohort study.Neurogastroenterol Motil2021;33:e13953

[69] VasantDH,MistryS,HamdyS.The val66met polymorphism of brain-derived neurotrophic factor is associated with human esophageal hypersensitivity.Neurogastroenterol Motil2013;25:162-e85

[70] EssaH,Raginis-zborowskaA,MichouE.PTU-182 Can response to pharyngeal stimulation in dysphagic stroke be predicted by bdnf genetic polymorphisms?.Gut2015;64:A143.1-A143

[71] MentzH,PaytonA,PendletonN.Homozygosity in the ApoE 4 polymorphism is associated with dysphagic symptoms in older adults.Dis Esophagus2015;28:97-103

[72] Raginis-ZborowskaA,PaytonA,HamdyS.Genetic determinants of swallowing impairments among community dwelling older population.Exp Gerontol2015;69:196-201

[73] KatzenschlagerR,CostaJ.Anticholinergics for symptomatic management of Parkinson’s disease.Cochrane Database Syst Rev2003;2002:CD003735 PMCID:PMC8728160

[74] SchuhMJ.Chronic anticholinergic toxicity discovered in a pharmacogenomics, polypharmacy patient.Sr Care Pharm2021;36:304-10

[75] EumS,Alliey-RodriguezN.Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders.Neuropsychopharmacology2021;46:1802-10 PMCID:PMC8358015

[76] KerstenH,MoldenE.Association between inherited CYP2D6/2C19 phenotypes and anticholinergic measures in elderly patients using anticholinergic drugs.Ther Drug Monit2014;36:125-30

[77] GurocakS,UreI.The impact of gene polymorphisms on the success of anticholinergic treatment in children with overactive bladder.Dis Markers2015;2015:732686 PMCID:PMC4488149

[78] VillaA,AbatiS.Diagnosis and management of xerostomia and hyposalivation.Ther Clin Risk Manag2015;11:45-51 PMCID:PMC4278738

[79] EndoT,FukamiT.Genetic polymorphisms of CYP2A6 affect the in vivo pharmacokinetics of pilocarpine.Pharmacogenet Genomics2008;18:761-72

[80] SigtermanKE,BonisPA,NumansME.Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.Cochrane Database Syst Rev2013;5:CD002095 PMCID:PMC7066537

[81] AddingtonWR,GillilandK.Tartaric acid-induced cough and the superior laryngeal nerve evoked potential.Am J Phys Med Rehabil1998;77:523-6

[82] WardRM.Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics.Paediatr Drugs2013;15:119-31 PMCID:PMC3616221

[83] Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.Expert Opin Drug Metab Toxicol2018;14:447-60 PMCID:PMC5942154

[84] HarrisDM,BurtonMC.Use of pharmacogenomics to guide proton pump inhibitor therapy in clinical practice.Dig Dis Sci2021;66:4120-7

[85] PatialRK.Baclofen in the treatment of intractable hiccups.J Assoc Physic India2002;50:1312-3

[86] McLaughlinMJ,Brunstrom-HernandezJ.Pharmacogenomic variability of oral baclofen clearance and clinical response in children with cerebral palsy.PMR2018;10:235-43 PMCID:PMC5880219

[87] FerrierJ.Domperidone as an unintended antipsychotic.Can Pharm J (Ott)2014;147:76-7 PMCID:PMC3962062